NCT02811822View on ClinicalTrials.gov

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

GMI-1271

Trial Locations (8)

Unknown

Vejle Hospital, Vejle

Medizinische Klinik/Abt. Innere Medizin V, Heidelberg

Cork University Hospital, Wilton, Cork

Beaumont Hospital, Dublin

National University Ireland - Galway, Galway

Sheffield Teaching Hospital, Sheffield

University College London Hospitals, London

LS9 7TF

Saint James's University Hospital Leeds, Leeds

All Listed Sponsors
lead

GlycoMimetics Incorporated

INDUSTRY

NCT02811822 - A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | Biotech Hunter | Biotech Hunter